Antibiotics and Chemotherapy最新文献

筛选
英文 中文
The Effect of Shock Gentamicin Concentrations on the Formation of Resistance and Small Colony Variants in Staphylococcus aureus 冲击庆大霉素浓度对金黄色葡萄球菌耐药性和小菌落变异体形成的影响
Antibiotics and Chemotherapy Pub Date : 2024-01-15 DOI: 10.37489/0235-2990-2023-68-9-10-25-33
V. Gostev, O. Kalinogorskaya, O. Sulian, P. Chulkova, J. Sopova, M. Velizhanina, V. Y. Pleshkov, V. Ageevets, S. V. Sidorenko
{"title":"The Effect of Shock Gentamicin Concentrations on the Formation of Resistance and Small Colony Variants in Staphylococcus aureus","authors":"V. Gostev, O. Kalinogorskaya, O. Sulian, P. Chulkova, J. Sopova, M. Velizhanina, V. Y. Pleshkov, V. Ageevets, S. V. Sidorenko","doi":"10.37489/0235-2990-2023-68-9-10-25-33","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-9-10-25-33","url":null,"abstract":"Гентамицин является одним из компонентов комбинированной терапии инфекционных эндокардитов, вызванных Staphylococcus aureus, включая метициллинорезистентные штаммы (methicillin-resistant S.aureus, MRSA). Цель исследования — анализ влияния десяти 6-часовых циклов воздействия высоких концентраций (16 мкг/мл) гентамицина in vitro на изменение фенотипа и генотипа аминогликозидочувствительных штаммов S.aureus, относящихся к четырём сиквенс-типам: ST5 (ATCC 29213), ST8, ST97 и ST22 (MRSA). Для всех штаммов, кроме ATCC 29213, после селекции отмечалось увеличение МПК гентамицина до 8–64 мкг/мл. Один штамм (SA0937) диссоциировал на три морфотипа, включая мелкоколониевый вариант (small colony variant, SCV). Вариант производного штамма SA0937 с колониями нормального размера характеризовался ассоциированной устойчивостью к даптомицину за счёт мутации P314L в MprF. Формирование устойчивости не сопровождалось изменением скорости роста, кроме морфотипа SCV. Для штамма ATCC 29213 после селекции отмечалось появление толерантности, проявляющейся в увеличении эффективного киллинга до 14 ч в 24-часовом time-killing эксперименте с концентрацией антибиотика 16 мкг/мл. У штамма ATCC 29213 выявлены мутации в пептидил т-РНК гидролазе (Pth). У трёх штаммов были обнаружены делеции в гене atpG, входящим в состав АТФ-синтазного комплекса. У остальных производных штаммов были выявлены делеции и мутации в генах метаболизма менахинона hepS, menA и трансляционном факторе элонгации G (fusA). Таким образом, использование гентамицина сопряжено с возможным быстрым формированием устойчивости и толерантности, не связанными с приобретением генов аминогликозид-модифицирующих ферментов. Выявление SCV ассоциировано с неблагоприятными клиническими исходами. При использовании комбинированной терапии необходимо учитывать, что существует возможность формирования устойчивости к даптомицину на фоне селекции гентамицином.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"225 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139622624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Antiviral Activity of Drugs from the Group of Polymer Electrolyte Derivatives against a Wide Range of Viruses 评估聚合物电解质衍生物类药物对多种病毒的抗病毒活性
Antibiotics and Chemotherapy Pub Date : 2024-01-15 DOI: 10.37489/0235-2990-2023-68-9-10-34-41
D. N. Razgulyaeva, A. M. Klabukov, A. V. Galochkina, A. V. Garshinina, O. N. Zhuravskaya, I. I. Gavrilova, V. A. Manakhov, N. Nesterova, A. Shtro, E. F. Panarin
{"title":"Evaluation of the Antiviral Activity of Drugs from the Group of Polymer Electrolyte Derivatives against a Wide Range of Viruses","authors":"D. N. Razgulyaeva, A. M. Klabukov, A. V. Galochkina, A. V. Garshinina, O. N. Zhuravskaya, I. I. Gavrilova, V. A. Manakhov, N. Nesterova, A. Shtro, E. F. Panarin","doi":"10.37489/0235-2990-2023-68-9-10-34-41","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-9-10-34-41","url":null,"abstract":"Background. The modern healthcare system is constantly improving and introducing new measures to protect the population from viral diseases, but the experience of the COVID-19 pandemic has shown that infections cannot always be controlled on global scale. In this regard, the development of new broad-spectrum antiviral drugs is more relevant than ever.The aim of the study was to investigate the antiviral activity and cytotoxicity of copolymers of sodium styrene sulfonate and vinyl monomers of various chemical structures, as well as to identify promising polymers for the development of new antiviral agents.Materials and methods. 14 copolymers of sodium styrene sulfonate (NaSS) with various functional comonomers were synthesized. Three viruses with different reproduction strategies and transmission methods — respiratory syncytial virus, influenza virus, and herpes virus — were selected for the assessment of antiviral activity.Results. The screening identified copolymers that showed high activity against all three viruses. It was found that the introduction of various functional groups into the structure of NaSS did not decrease antiviral activity, but significantly reduced cytotoxicity. The molecular weight has also shown a noticeable effect on the activity. Different sensitivity of viruses and cells to the studied polymers was revealed, likely due to the structural features of the virus shell and cell wall.Conclusions. The results demonstrate the potential of sodium styrene sulfonate copolymers as a model for developing a broad-spectrum antiviral drug.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139529351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of Antibacterial Drugs’ Nephrotoxicity in the RPTEC Cell Line 在 RPTEC 细胞系中研究抗菌药物的肾毒性
Antibiotics and Chemotherapy Pub Date : 2024-01-15 DOI: 10.37489/0235-2990-2023-68-9-10-42-45
V. Evteev, I. S. Semenova, N. Bunyatyan, A. Prokofiev, V. G. Kukes
{"title":"Study of Antibacterial Drugs’ Nephrotoxicity in the RPTEC Cell Line","authors":"V. Evteev, I. S. Semenova, N. Bunyatyan, A. Prokofiev, V. G. Kukes","doi":"10.37489/0235-2990-2023-68-9-10-42-45","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-9-10-42-45","url":null,"abstract":"The created cell line of human proximal renal tubules RPTEC/TERT1 showed maximum compliance with primary human RPTEC, which makes it optimal for use in studies of the nephrotoxic properties of xenobiotics. Transepithelial resistance measurement (TEER) is a valuable non-invasive method that can be used to quantify the integrity of the cell barrier at various stages of cell growth and differentiation, as well as to predict the toxicity and permeability of drugs.The aim of the study was to examine the dynamics of changes in transepithelial resistance in the model of the RPTEC/TERT1 cell line during incubation with drugs with nephrotoxic effects.Material and methods. The human proximal renal tubule cell line RPTEC/TERT was obtained from the ATCC cell culture bank. Cells at passage 14 were used in the experiment. The following drugs were studied: cisplatin: 2.5 mcg/ml; vancomycin: 50 mcg/ml; doripenem — 20mcg/ml; cefepim — 150mcg/ml. 4–5 repetitions were performed for each concentration of the drug in the experiment. THEER measurements were carried out 4–5 times for each well.Results. Cisplatin, vancomycin, doripenem, and cefepim in the concentrations used do not show a cytotoxic effect on the RPTEC cell line according to TEER dynamics. ","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":" 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139621467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic Potential of Marine Actinomycetes of the Genera Streptomyces and Nocardiopsis 链霉菌属和诺心菌属海洋放线菌的抗生素潜力
Antibiotics and Chemotherapy Pub Date : 2023-07-18 DOI: 10.37489/0235-2990-2023-68-3-4-11-18
O. N. Sineva, V. Sadykova, O. P. Bychkova, T. D. Ivankova, K. V. Malysheva, N. Markelova
{"title":"Antibiotic Potential of Marine Actinomycetes of the Genera Streptomyces and Nocardiopsis","authors":"O. N. Sineva, V. Sadykova, O. P. Bychkova, T. D. Ivankova, K. V. Malysheva, N. Markelova","doi":"10.37489/0235-2990-2023-68-3-4-11-18","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-3-4-11-18","url":null,"abstract":"Due to the emergence of antibiotic resistance in pathogenic microorganisms, it is urgent to search for producers of new antimicrobial metabolites. Actinomycetes are gram-positive mycelial bacteria that produce a large number of antibiotics used in medicine and the agro-industrial complex. Currently, researchers are focused on the search for actinomycetes in ecological niches such as freshwater and marine reservoirs, zones with extreme natural conditions (permafrost soils, glaciers, desert, saline soils, etc.). In this study, cultures of marine actinomycetes were restored after 15 years of storage under vaseline oil. It was shown that all strains retained viability and antibiotic activity at a high level. Based on the results of 16S rRNA gene sequence analysis, the species were identified as: Streptomyces sampsonii 6N, Streptomyces sampsonii 8N, Streptomyces sampsonii 521N, Streptomyces halstedii 22N, Streptomyces brevispora 12N, Streptomyces hirsutus 23N, Streptomyces niveus 14N, Nocardiopsis alba 24N, Nocardiopsis alba 73N, Nocardiopsis alba 85N, Nocardiopsis alba 106N, Nocardiopsis alborubida 722N, Nocardiopsis umidischolae 755N, Nocardiopsis umidischolae 763N. These strains of actinobacteria possessed significant antibiotic activity against the following pathogens: Micrococcus luteus ATCC 9341, Staphylococcus aureus INA 00985, Bacillus subtilis ATCC 6633, Staphylococcus aureus INA 00761 (MRSA — Staphylococcus aureus), Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Pectobacterium carotovorum VKM-B1247, Saccharomyces cerevisiae INA 01042, Candida albicans ATCC 14053, Aspergillus niger ATCC 16404, Aspergillus fumigatus CPB F -37, Fusarium solani VKPM F-890, Fusarium oxysporum VKPM F-148. Therefore, this study evaluated the marine actinomycetes can be potential producers of the novel antibiotics.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80912780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Acute Toxicity of Quinazoline Derivative 3-[2-oxo-2-(4-Phenylpiperazine-1-yl)Ethyl]quinazoline-4(3h)-oh Active against Opportunistic Microorganisms 喹唑啉衍生物3-[2-氧-2-(4-苯基哌嗪-1-酰基)乙基]喹唑啉-4(3h)-oh对条件微生物的急性毒性评价
Antibiotics and Chemotherapy Pub Date : 2023-07-18 DOI: 10.37489/0235-2990-2023-68-3-4-30-34
N. M. Gabitova, A. A. Tsibizova, A. Ozerov, M. Samotrueva
{"title":"Assessment of Acute Toxicity of Quinazoline Derivative 3-[2-oxo-2-(4-Phenylpiperazine-1-yl)Ethyl]quinazoline-4(3h)-oh Active against Opportunistic Microorganisms","authors":"N. M. Gabitova, A. A. Tsibizova, A. Ozerov, M. Samotrueva","doi":"10.37489/0235-2990-2023-68-3-4-30-34","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-3-4-30-34","url":null,"abstract":"The study is devoted to the study of acute toxicity of a new quinazoline compound — 3-[2-Oxo-2-(4-phenylpiperazine-1-yl)ethyl]quinazoline-4(3H)-one (VMA-10-21), promising as an antimicrobial agent active against opportunistic microorganisms. Purpose. Assessment of acute toxicity of the quinazoline derivative 3-[2-oxo-2-(4-phenylpiperazine-1yl)ethyl] quinazoline-4(3h)-oh, exhibiting antimicrobial activity. Material and methods. All experiments were carried out on non-linear mature female rats with a body weight of 180–190 g. Female individuals were in the diestrus stage. The rats were divided into groups (n=6) by a random sample, there were 4 individuals in each group and were kept in cages for a week before the experiment, getting used to laboratory conditions: animals receiving intragastric equiobjection of distilled water (control); experimental animals treated with the compound VMA-10-21 at doses of 1000, 2000; 5000 mg/kg (the doses were selected based on the fact that the study of the toxicity of pyrimidine derivatives with a similar chemical structure showed their relative safety and the absence of lethality from a dose of 500 mg/kg). Results. Assessment of acute toxicity of the quinazoline derivative 3-[2-oxo-2-(4-phenylpiperazine-1yl)ethyl]quinazoline-4(3h)-oh with intragastric administration showed that this compound belongs to class 5 toxicity and is low-toxic according to. Under these conditions, and for LD₅₀, the maximum dose is 5000 mg/kg. However, despite the results obtained, when this compound was administered at a dose of 5000 mg/kg, changes in hemoglobin, the number of leukocytes and platelets, as well as total protein were observed, which may indicate the possible development of pathological changes in the hematopoietic and hepatobiliary systems. Conclusion. Thus, the quinazoline derivative 3-[2-oxo-2-(4-phenylpiperazine-1yl)ethyl]quinazoline-4(3h)-oh with intragastric administration is low-toxic and belongs to the 5th class of toxicity, and therefore the maximum dose is 5000 mg/kg for LD₅₀. However, given the fact that there are changes in hematological and biochemical parameters, this compound needs to be studied in detail under the conditions of course effects on the body of animals.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89792356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of the Mechanism of Antiviral Activity of Cytovir®-3 Against Respiratory Viruses In Vitro Cytovir®-3体外抗呼吸道病毒作用机制的研究
Antibiotics and Chemotherapy Pub Date : 2023-07-18 DOI: 10.37489/0235-2990-2023-68-3-4-4-10
V. Zarubaev, V. S. Smirnov, T. A. Kudryavtseva, S. Petlenko, A. V. Slita, H. Minh, V. Zaplutanov
{"title":"Study of the Mechanism of Antiviral Activity of Cytovir®-3 Against Respiratory Viruses In Vitro","authors":"V. Zarubaev, V. S. Smirnov, T. A. Kudryavtseva, S. Petlenko, A. V. Slita, H. Minh, V. Zaplutanov","doi":"10.37489/0235-2990-2023-68-3-4-4-10","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-3-4-4-10","url":null,"abstract":"Introduction. The requirements of modern clinical guidelines for the treatment of respiratory viral infections suggest the possibility of identifying a specific viral pathogen. In this regard, the search for drugs with selective activity against respiratory syncytial virus and parainfluenza virus is relevant. The purpose of the work is to study the antiviral activity of the drug Cytovir®-3 in vitro in relation to the cytopathogenic effect of respiratory viruses (parainfluenza virus and respiratory syncytial virus). Material and methods. The antiviral effect of Cytovir®-3 in comparison with Umifenovir against parainfluenza virus and respiratory syncytial virus was studied on Vero cell culture. Drugs were administered 1 hour before (prophylactic regimen) and 1 hour after (treatment regimen) infection of the cell culture with respiratory viruses. The working range of concentrations of the studied drugs was calculated based on the values of 50% cytotoxic concentration calculated based on the results of a quantitative microtetrazole test. Results and discussion. The drug Cytovir®-3 in two schemes of application (therapeutic or prophylactic) showed its antiviral efficacy in vitro against respiratory syncytial virus and parainfluenza virus due in the non-toxic range (0–794 µg/ml). At the same time, the suppressive effect of the drug Cytovir®-3 against the parainfluenza virus begins at lower concentrations of the drug with its early (preventive) introduction into cell culture (250 mcg/ml). Conclusion. Antiviral activity of Cytovir®-3 has been proven in vitro against parainfluenza virus and respiratory syncytial virus. At the same time, in all series of experiments, Cytovir®-3 had a higher index of selectivity of antiviral action than that of the comparison drug Umifenovir.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75311053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibacterial Activity of the Halogen- and Nitro Derivatives of Benzimidazole Against Bacillus Subtilis 苯并咪唑卤素和硝基衍生物对枯草芽孢杆菌的抑菌活性研究
Antibiotics and Chemotherapy Pub Date : 2023-07-18 DOI: 10.37489/0235-2990-2023-68-3-4-19-24
R. Begunov, D. Egorov, A. V. Chetvertakova, L. I. Savina, A. Zubishina
{"title":"Antibacterial Activity of the Halogen- and Nitro Derivatives of Benzimidazole Against Bacillus Subtilis","authors":"R. Begunov, D. Egorov, A. V. Chetvertakova, L. I. Savina, A. Zubishina","doi":"10.37489/0235-2990-2023-68-3-4-19-24","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-3-4-19-24","url":null,"abstract":"Background. Antibiotic resistance of bacteria is a serious concern for modern medicine. The search for new compounds with a pronounced antibacterial effect is an urgent task of pharmaceutical chemistry. The aim of the study was to assess nfluence of the structure of benzimidazole and its derivatives the ability to inhibit the growth of gram-positive bacteria Bacillus subtilis. Materials and methods. Antibacterial activity of diazaheterocycles was evaluated by the method of serial dilutions. Сoncentrations from 0,06 to 1000 µg/l were used. Тhe minimum inhibitory concentration (MIC) of benzimidazole derivatives against Bacillus subtilis BKM B-407 was determined. The antibacterial effect of the studied halogen- and nitrobenzimidazoles was compared with the antimicrobial activity of benzimidazole. Results. The antimicrobial activity of the 12 benzimidazole derivatives was established. 2-trifluoromethylbenzimidazoles containing halogen atoms in the phenylene fragment had the most pronounced inhibitory effect. The dihalogenated derivatives exhibited greater antibacterial activity than the compounds with one halogen atom in the benzene ring. 5,6-dibromo-2-(trifluoromethyl)benzimidazole was the most active compound with an MIC of 0.49 µg/mL, comparable to the commercial antibiotic tetracycline. The antibacterial activity of erythromycin is a half that of this substance. Conclusions. Polyhalogen derivatives of benzimidazole are promising compounds for the development of new antimicrobial drugs against Gram-positive bacteria.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87370183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and Laboratory Characteristics of Patients with COVID-19 on the Background of Cardiovascular Diseases 以心血管疾病为背景的COVID-19患者的临床和实验室特征
Antibiotics and Chemotherapy Pub Date : 2023-07-18 DOI: 10.37489/0235-2990-2023-68-3-4-46-51
Z. A. Kambachokova, Z. A. Akhkubekova, R. Aramisova, D. E. Altudova, L. A. Kagazheva, M. A. Shokueva, A. A. Kambachokova, A. B. Kankulova, A. M. Urusbiev, Yusufzai Abdul Vadzhid, I. A. Kochesokova
{"title":"Clinical and Laboratory Characteristics of Patients with COVID-19 on the Background of Cardiovascular Diseases","authors":"Z. A. Kambachokova, Z. A. Akhkubekova, R. Aramisova, D. E. Altudova, L. A. Kagazheva, M. A. Shokueva, A. A. Kambachokova, A. B. Kankulova, A. M. Urusbiev, Yusufzai Abdul Vadzhid, I. A. Kochesokova","doi":"10.37489/0235-2990-2023-68-3-4-46-51","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-3-4-46-51","url":null,"abstract":"The research studied the clinical and laboratory characteristics of COVID-19 patients against the background of cardiovascular diseases. A high prevalence of cardiovascular diseases (CVD) was revealed among COVID-19 patients: arterial hypertension (93.4%), chronic heart failure (60.9%), cardiac arrhythmias (40.1%), coronary heart disease (21.9%). A reliable correlation was established between the timing of hospitalization from the onset of the disease and the severity of the infection, mortality was higher in persons hospitalized on the 5–7 day of the disease (59.8%). Patients with CVD are significantly more likely to develop complications, as well as higher deaths (11.53% vs. 4.30%). Pulmonary embolism (44%), acute respiratory distress syndrome (22%), acute kidney injury (20.6%) prevailed in the structure of causes of death. Gender differences in the course and outcomes of COVID-19 were found: the severity of the course and mortality rates were higher among males. According to clinical and laboratory indicators, patients with diseases of the cardiovascular system had a more severe course and a high degree of immuno-inflammatory reactions compared with the group of patients without a premorbid background. Upon admission to the hospital, patients with COVID-19 and CVD were significantly more likely to have a lesion of the pulmonary parenchyma of CT 3 and CT 4 (P<0.05), whereas in the group without concomitant cardiac pathology, lung lesion corresponded to CT 1 (P<0.05); CT of the lungs in dynamics showed differences in the study groups: in patients with COVID-19 and CVD, CT 3 was recorded significantly more often, and in the comparison group — CT 1 (45% vs. 10%, (P<0.05)).","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81470572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro and in vivo Immunoadjuvant Effects of the Enzymatically Modified Fucoidan 酶修饰岩藻糖聚糖的体外和体内免疫佐剂作用
Antibiotics and Chemotherapy Pub Date : 2023-07-18 DOI: 10.37489/0235-2990-2023-68-3-4-25-29
T. Kuznetsova, T. Smolina, L. A. Ivanushko, E. V. Persiyanova, A. Silchenko, N. Besednova
{"title":"In vitro and in vivo Immunoadjuvant Effects of the Enzymatically Modified Fucoidan","authors":"T. Kuznetsova, T. Smolina, L. A. Ivanushko, E. V. Persiyanova, A. Silchenko, N. Besednova","doi":"10.37489/0235-2990-2023-68-3-4-25-29","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-3-4-25-29","url":null,"abstract":"Objectives. No sulfated polysaccharides (fucoidans) has been declared as the pharmaceutical substances, adjuvants, etc., which is associated with the problems of obtaining the structurally characterized and homogeneous samples or their oligomeric fractions that retain high biological activity. The highly purified fucoidan with regular reproducible structural characteristics (F1) was obtained by enzymatic hydrolysis of native fucoidan (F2). Aim. The comparative study of fucoidans from the brown alga Fucus evanescens (F1 and F2) effects on the effector functions of innate and adaptive immunity cells loaded with ovalbumin (OVA) in vitro and in vivo. Material and methods. Fucoidan F1 — the enzymatically modified product of native fucoidan; F2 — the native fucoidan. The fucoidans effects on the expression level of the main immunophenotypic markers of innate and adaptive immunity (neutrophils, monocytes, natural killers, lymphocytes) cells in vitro were studied by methods of flow cytometry. The fucoidans effects on the production of serum OVA-specific antibodies (IgG, IgG1, IgG2а) and cytokines (IFNγ, IL-2, IL-10, IL-12) were detected in BALB/c mice immunized with OVA. Results. The tested fucoidans activate the effector functions of innate and adaptive immunity cells loaded with OVA in vitro and act as adjuvants, stimulating both Th1 (IgG2а, INFγ, IL-2) and Th2 (IgG1, IL-10) immune response to OVA in vivo. Conclusions. The immunoadjuvant effect of the enzymatically modified fucoidan (F1) on effector functions of innate and adaptive immunity cells are comparable to those of the native fucoidan (F2). The findings determine the possibility of F1 use as an adjuvant for a wide range of prophylactic and therapeutic vaccines.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84357376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy COVID-19抗白细胞介素治疗有效性的meta分析和间接比较的系统评价
Antibiotics and Chemotherapy Pub Date : 2023-07-18 DOI: 10.37489/0235-2990-2023-68-3-4-52-65
Y. Gomon, A. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. Sultanova, Y. Balykina
{"title":"A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy","authors":"Y. Gomon, A. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. Sultanova, Y. Balykina","doi":"10.37489/0235-2990-2023-68-3-4-52-65","DOIUrl":"https://doi.org/10.37489/0235-2990-2023-68-3-4-52-65","url":null,"abstract":"Aim. Evaluation of the effectiveness of anti-interleukin drugs used in the pathogenetic therapy of COVID-19 in relation to the relative risks of 28-day mortality and the odds ratio of 14-day improvement of symptoms of the disease. Materials and methods. A systematic review of publications concerning the evaluation of the effectiveness of these drugs recommended for use as COVID-19 pathogenetic therapy, with meta-analysis and indirect comparison of the data obtained, was carried out. Results. The meta-analysis included 15 randomized and 8 non-randomized studies. In direct comparison of anti-interleukin drugs with controls, it was demonstrated that only tocilizumab and anakinra surpass standard therapy in terms of the relative risk of 28-day mortality (RR 0.85 [95% CI 0.74; 0.97] and 0.5 [95% CI 0.32; 0.80], respectively). Statistically reliable data were also obtained in favor of the effectiveness of levilimab in comparison with standard therapy according to the criterion of «improvement by the 14th day of the disease», which was 2.29 [1.31; 4.01]. With an indirect comparison of tocilizumab and anakinra, the latter showed greater effectiveness in reducing the 28-day mortality rate: the RR was 1.2 [95% CI 1.16; 1.25], P=0.0001. Conclusion. The meta-analysis of the results of the systematic review demonstrated the effectiveness of tocilizumab and anakinra in relation to the 28-day mortality rate, and levilimab in relation to the indicator «Improvement by the 14th day of the disease».","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81795868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信